Related Experiment Videos
Angiostatin expression in endometrial cancer
Hiromitsu Yabushita1, Mari Noguchi, Shingo Kinoshita
1Department of Obstetrics and Gynecology, School of Medicine, Aichi Medical University, Yazako, Nagakute-cho, Aichi-gun, Aichi 480-1195, Japan. yab@aichi-med-u-ac.jp
Oncology Reports
|October 11, 2002
Summary
Angiostatin, an inhibitor of tumor growth, and vascular endothelial growth factor (VEGF) were studied in endometrial cancer. Positive angiostatin and negative VEGF expression predict better outcomes in stage I disease.
Area of Science:
- Oncology
- Pathology
Background:
- Angiostatin inhibits neovascularization, tumor growth, and metastasis.
- Vascular Endothelial Growth Factor (VEGF) plays a role in tumor angiogenesis.
Purpose of the Study:
- To investigate the prognostic significance of angiostatin and VEGF expression in stage I endometrial carcinoma.
- To correlate angiostatin and VEGF expression with clinicopathological features and patient survival.
Main Methods:
- Immunohistochemical examination of angiostatin and VEGF expression in 57 primary endometrial tumors.
- Assessment of microvessel density.
- Correlation with myometrial invasion, histological grade, lymph-vascular space involvement, and disease-free survival.
Main Results:
- Angiostatin expression was not associated with depth of invasion, grade, or lymph-vascular space involvement.
- VEGF expression was enhanced in tumors with lymph-vascular space involvement.
- Microvessel density correlated with VEGF but not angiostatin expression.
- Disease-free survival was longer in patients with angiostatin-positive tumors.
- No recurrence was observed in patients with both angiostatin-positive and VEGF-negative tumors.
Conclusions:
- Negative VEGF expression and positive angiostatin expression are significant prognostic factors in endometrial carcinoma.
- These markers may aid in predicting outcomes for stage I endometrial cancer patients.